Influenza A virus infection predisposes hosts to secondary infection with different Streptococcus pneumoniae serotypes with similar outcome but serotype-specific manifestation

Infection and Immunity

Volumn 84, Issue 12, 2016, Pages 3445-3457

  Sharma Chawla, Niharika ^a,b   Sender, Vicky ^c   Kershaw, Olivia ^d   Gruber, Achim D ^d   Volckmar, Julia ^a   Henriques Normark, Birgitta ^c,e   Stegemann Koniszewski, Sabine ^a,b   Bruder, Dunja ^a,b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; INTERLEUKIN 6; KERATINOCYTE CHEMOATTRACTANT; LIPOPOLYSACCHARIDE INDUCED CXC CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; IMMUNOPATHOLOGY; INCIDENCE; INFLAMMATION; INFLUENZA A; INFLUENZA A VIRUS; INNATE IMMUNITY; LETHALITY; LUNG; LUNG ALVEOLUS MACROPHAGE; MEDIATOR RELEASE; MIXED INFECTION; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; SECONDARY INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC DISEASE; VIRAL CLEARANCE; VIRUS LOAD; ANIMAL; CLASSIFICATION; COMPLICATION; IMMUNOLOGY; MICROBIOLOGY; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; PNEUMOCOCCAL INFECTION; VIROLOGY;

ANIMALS; COINFECTION; FEMALE; IMMUNITY, INNATE; INFLUENZA A VIRUS; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; VIRAL LOAD;

EID: 85002890766     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00422-16     Document Type: Article

References (53)

1. Taubenberger JK, Morens DM. 2006. 1918 influenza: the mother of all pandemics. Emerg Infect Dis 12:15-22. http://dx.doi.org/10.3201/eid1209.05-0979
2. Chien YW, Klugman KP, Morens DM. 2009. Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med 361:2582-2583. http://dx.doi.org/10.1056/NEJMc0908216
3. McCullers JA. 2014. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 12:252-262. http://dx.doi.org/10 .1038/nrmicro3231
4. Khan MN, Pichichero ME. 2014. The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.Hum Vaccin Immunother 10:3688-3699. http://dx.doi.org/10.4161/21645515 .2014.979631
5. van den Boogaard FE, van Gisbergen KP, Vernooy JH, Medema JP, Roelofs JJ, van Zoelen MA, Endeman H, Biesma DH, Boon L, van't Veer C, de Vos AF, van der Poll T. 2016. Granzyme A impairs host defense during Streptococcus pneumoniae pneumonia. Am J Physiol Lung Cell Mol Physiol 311(2):L507-L516. http://dx.doi.org/10.1152/ajplung.00116.2016
6. Anonymous. 2007. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 82:93-104
7. Chiavolini D, Pozzi G, Ricci S. 2008. Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev 21:666-685. http://dx.doi.org/10.1128/CMR.00012-08
8. Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Rückinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, O'Brien KL, Scott JA, Lipsitch M. 2010. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51:692-699. http://dx.doi.org/10.1086/655828
9. de Vos AF, Dessing MC, Lammers AJ, de Porto AP, Florquin S, de Boer OJ, de Beer R, Terpstra S, Bootsma HJ, Hermans PW, van't Veer C, van der Poll T. 2015. The polysaccharide capsule of Streptococcus pneumonia partially impedes MyD88-mediated immunity during pneumonia in mice. PLoS One 10:e0118181. http://dx.doi.org/10.1371/journal.pone .0118181
10. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH. 2015. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 28:871-899. http://dx .doi.org/10.1128/CMR.00024-15
11. Weinberger DM, Trzcinski K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. 2009. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 5:e1000476. http://dx.doi.org/10.1371/journal.ppat.1000476
12. Wartha F, Beiter K, Albiger B, Fernebro J, Zychlinsky A, Normark S, Henriques-Normark B. 2007. Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol 9:1162-1171. http://dx.doi.org/10.1111/j.1462-5822 .2006.00857.x
13. Camberlein E, Cohen JM, Jose R, Hyams CJ, Callard R, Chimalapati S, Yuste J, Edwards LA, Marshall H, van Rooijen N, Noursadeghi M, Brown JS. 2015. Importance of bacterial replication and alveolar macrophage-independent clearance mechanisms during early lung infection with Streptococcus pneumoniae. Infect Immun 83:1181-1189. http://dx .doi.org/10.1128/IAI.02788-14
14. Rodgers GL, Klugman KP. 2011. The future of pneumococcal disease prevention. Vaccine 29(Suppl 3):C43-C48. http://dx.doi.org/10.1016/j .vaccine.2011.07.047
15. Sandgren A, Albiger B, Orihuela CJ, Tuomanen E, Normark S, Henriques-Normark B. 2005. Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans. J Infect Dis 192:791-800. http://dx.doi.org/10.1086/432513
16. Blomberg C, Dagerhamn J, Dahlberg S, Browall S, Fernebro J, Albiger B, Morfeldt E, Normark S, Henriques-Normark B. 2009. Pattern of accessory regions and invasive disease potential in Streptococcus pneumoniae. J Infect Dis 199:1032-1042. http://dx.doi.org/10.1086/597205
17. Luján M, Gallego M, Belmonte Y, Fontanals D, Vallès J, Lisboa T, Rello J. 2010. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 36:1073-1079. http://dx.doi .org/10.1183/09031936.00176309
18. Sun K, Gan Y, Metzger DW. 2011. Analysis of murine genetic predisposition to pneumococcal infection reveals a critical role of alveolar macrophages in maintaining the sterility of the lower respiratory tract. Infect Immun 79:1842-1847. http://dx.doi.org/10.1128/IAI.01143-10
19. Haste LV, Hulland K, Bolton S, Yesilkaya H, McKechnie K, Andrew PW. 2014. Development and characterisation of a long term murine model of Streptococcus pneumoniae infection of the lower airways. Infect Immun 82:3289-3298. http://dx.doi.org/10.1128/IAI.01623-14
20. Robinson KM, Kolls JK, Alcorn JF. 2015. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol 34:59-67. http://dx.doi.org/10.1016/j.coi.2015.02.002
21. Hussell T, Cavanagh MM. 2009. The innate immune rheostat: influence on lung inflammatory disease and secondary bacterial pneumonia. Biochem Soc Trans 37:811-813. http://dx.doi.org/10.1042/BST0370811
22. Ballinger MN, Standiford TJ. 2010. Postinfluenza bacterial pneumonia: host defenses gone awry. J Interferon Cytokine Res 30:643-652. http://dx .doi.org/10.1089/jir.2010.0049
23. Chertow DS, Memoli MJ. 2013. Bacterial coinfection in influenza: a grand rounds review. JAMA 309:275-282. http://dx.doi.org/10.1001/jama .2012.194139
24. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, Lawrence T, van Rijt LS, Lambrecht BN, Sirard JC, Hussell T. 2008. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 205:323-329. http://dx.doi.org/10.1084/jem.20070891
25. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der Poll T. 2004. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 172:7603-7609. http://dx.doi.org/10.4049/jimmunol.172.12.7603
26. Klugman KP, Chien YW, Madhi SA. 2009. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine 27(Suppl 3):C9-C14. http://dx.doi.org/10.1016/j.vaccine.2009.06.007
27. Stegemann S, Dahlberg S, Kröger A, Gereke M, Bruder D, Henriques-Normark B, Gunzer M. 2009. Increased susceptibility for superinfection with Streptococcus pneumoniae during influenza virus infection is not caused by TLR7-mediated lymphopenia. PLoS One 4:e4840. http://dx.doi .org/10.1371/journal.pone.0004840
28. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497
29. McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B. 2010. Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 202:1287-1295. http://dx.doi.org/10.1086/656333
30. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. 2003. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype-and clone-specific differences in invasive disease potential. J Infect Dis 187:1424-1432. http://dx.doi.org/10.1086/374624
31. Sandgren A, Sjostrom K, Olsson-Liljequist B, Christensson B, Samuelsson A, Kronvall G, Henriques Normark B. 2004. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 189:785-796. http://dx.doi.org/10.1086/381686
32. Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon S, Henriques-Normark B. 2006. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42:451-459. http://dx.doi.org/10.1086/499242
33. Blevins LK, Wren JT, Holbrook BC, Hayward SL, Swords WE, Parks GD, Alexander-Miller MA. 2014. Coinfection with Streptococcus pneu-moniae negatively modulates the size and composition of the ongoing influenza-specific CD8(+) T cell response. J Immunol 193:5076-5087. http://dx.doi.org/10.4049/jimmunol.1400529
34. Short KR, Reading PC, Brown LE, Pedersen J, Gilbertson B, Job ER, Edenborough KM, Habets MN, Zomer A, Hermans PW, Diavatopoulos DA, Wijburg OL. 2013. Influenza-induced inflammation drives pneumococcal otitis media. Infect Immun 81:645-652. http://dx.doi.org/10.1128/IAI.01278-12
35. Wren JT, Blevins LK, Pang B, King LB, Perez AC, Murrah KA, Reimche JL, Alexander-Miller MA, Swords WE. 2014. Influenza A virus alters pneumococcal nasal colonization and middle ear infection independently of phase variation. Infect Immun 82:4802-4812. http://dx.doi.org/10 .1128/IAI.01856-14
36. Ahn JG, Choi SY, Kim DS, Kim KH. 2015. Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines. Infect Dis (Lond) 47:385-392. http://dx.doi.org/10 .3109/00365548.2014.1001997
37. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. 2007. Induction of pro-and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 57:82-89
38. Mina MJ, Klugman KP. 2014. The role of influenza in the severity and transmission of respiratory bacterial disease. Lancet Respir Med 2:750-763. http://dx.doi.org/10.1016/S2213-2600(14)70131-6
39. Harvey RM, Hughes CE, Paton AW, Trappetti C, Tweten RK, Paton JC. 2014. The impact of pneumolysin on the macrophage response to Streptococcus pneumoniae is strain-dependent. PLoS One 9:e103625. http://dx .doi.org/10.1371/journal.pone.0103625
40. Ghoneim HE, Thomas PG, McCullers JA. 2013. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 191:1250-1259. http://dx.doi.org/10.4049/jimmunol .1300014
41. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J, van Rooijen N, van der Poll T. 2003. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167:171-179. http://dx.doi.org/10.1164/rccm .200207-698OC
42. Schneider C, Nobs SP, Heer AK, Kurrer M, Klinke G, van Rooijen N, Vogel J, Kopf M. 2014. Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. PLoS Pathog 10:e1004053. http://dx.doi.org/10 .1371/journal.ppat.1004053
43. Purnama C, Ng SL, Tetlak P, Setiagani YA, Kandasamy M, Baalasubramanian S, Karjalainen K, Ruedl C. 2014. Transient ablation of alveolar macrophages leads to massive pathology of influenza infection without affecting cellular adaptive immunity. Eur J Immunol 44:2003-2012. http://dx.doi.org/10.1002/eji.201344359
44. Wilson R, Cohen JM, Jose RJ, de Vogel C, Baxendale H, Brown JS. 2015. Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses. Mucosal Immunol 8:627-639. http://dx.doi.org/10.1038/mi .2014.95
45. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. 2007. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 85:85-92. http://dx.doi.org/10.1038/sj.icb.7100026
46. Peper RL, Van Campen H. 1995. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb Pathog 19:175-183. http://dx.doi.org/10.1006/mpat.1995.0056
47. Hussell T, Pennycook A, Openshaw PJ. 2001. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 31:2566-2573. http://dx.doi.org/10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
48. Ellis GT, Davidson S, Crotta S, Branzk N, Papayannopoulos V, Wack A. 2015. TRAIL+monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection. EMBO Rep 16:1203-1218. http://dx.doi.org/10 .15252/embr.201540473
49. Karlstrom A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA. 2011. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 204:1358-1366. http://dx.doi.org/10.1093/infdis/jir522
50. Ghoneim HE, McCullers JA. 2014. Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis 209:1459-1468. http://dx .doi.org/10.1093/infdis/jit653
51. Edgeworth D, Brohan J, O'Neill S, Maher M, Breen D, Murphy D. 2013. Pulmonary sequelae of severe H1N1 infection treated with high frequency oscillatory ventilation. Ir Med J 106:249-252
52. Luyt C-E, Combes A, Becquemin M-H, Beigelman-Aubry C, Hatem S, Brun A-L, Zraik N, Carrat F, Grenier PA, Richard J-CM, Mercat A, Brochard L, Brun-Buisson C, Chastre J. 2012. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest 142: 583-592. http://dx.doi.org/10.1378/chest.11-2196
53. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. 2016. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 3:CD010406. http://dx.doi.org/10.1002/14651858.CD010406.pub2